<DOC>
	<DOCNO>NCT00528879</DOCNO>
	<brief_summary>The purpose clinical research study learn whether dapagliflozin help reduce blood sugar level participant Type 2 diabetes well control metformin alone . The safety treatment also study .</brief_summary>
	<brief_title>A Phase III Study BMS-512148 ( Dapagliflozin ) Patients With Type 2 Diabetes Who Are Not Well Controlled Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Key Inclusion Criteria Males female , 18 77 year old , type 2 diabetes inadequate glycemic control Participants receive metformin total daily dose ≥1500 mg per day least 8 week Cpeptide ≥1.0 ng/mL Body mass index ≤45.0 kg/m^2 Serum creatinine level &lt; 1.50 mg/dL men &lt; 1.40 mg/dL woman . Key Exclusion Criteria Aspartate aminotransferase and/or alanine aminotransferase level &gt; 3.0 time upper limit normal Serum total bilirubin level &gt; 2 mg/dL Creatinine kinase level &gt; 3 time upper limit normal Symptoms severely uncontrolled diabetes Serum creatinine level ≥1.50 mg/dL men ≥1.40 mg/dL woman Currently unstable serious cardiovascular , renal , hepatic , hematologic , oncologic , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>